Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

New Haven eyes biospace construction standards

The New Haven City Plan department has proposed updating the city’s zoning laws to allow for larger developments in exchange for more environmentally friendly construction...

| By Kelley Gipson

Rebiotix and Ferring report positive Phase 3 results

Rebiotix and Ferring Pharmaceuticals announced positive preliminary findings from their ongoing pivotal Phase 3 trial of the investigational microbiome-based treatment, RBX2660. RBX2660 is being developed...

| By Kelley Gipson

PwC announces Check-In digital platform

Check-In, from BioCT member pwc, is a precision platform made up of two products built with people’s privacy in mind. The platform provides businesses with near real-time...

| By Kelley Gipson

NanoViricides collaborating on COVID-19 treatment

Antiviral developer NanoViricides says it has inked a confidential disclosure agreement with a “leading pharmaceutical company” in Asia to explore collaborating on the Shelton company’s proposed COVID-19...

| By Kelley Gipson

Alexion to acquire California-based Portola

Alexion will acquire Portola, a California-based commercial-stage biopharmaceutical company focused on life-threatening blood-related disorders. Portola’s commercialized medicine, Andexxa®, is the first and only approved Factor Xa...

| By Kelley Gipson

BARDA funds Tangen diagnostic platform

BARDA has awarded Tangen Biosciences the Second Option of a contract to develop a molecular diagnostic platform that can be used by the company to rapidly...

| By Kelley Gipson

Pfizer adds Lyme Disease in deal with Valneva

In the midst of their $500 million program to build a Covid-19 vaccine with BioNTech, Pfizer has announced a sizable deal to commercialize a vaccine...